Oxford’s mission is to manufacture, package and distribute affordable, high quality generic drug products to improve the lives of patients. Oxford owns multitude of ANDAs which are currently being manufactured, packaged, then put on stability under a stringent validation program. Oxford expects to file initial products for commercial approval by early summer 2018. Oxford also intends to act as a CMO or CPO once its systems are validated and procuring required approvals. Oxford prides itself in making drugs right here in the USA!